發(fā)布時(shí)間:
2023
-
06
-
26
點(diǎn)擊次數(shù):
0
所屬職位：
首席科學(xué)家
所屬公司：
華潤醫(yī)藥
個(gè)人簡介：
陳波博士是海外高層次人才特聘專家, 目前擔(dān)任華潤醫(yī)藥集團(tuán)首席科學(xué)家, 在生物技術(shù)和制藥行業(yè)擁有超過20年的國際職業(yè)生涯，包括在美國NIH，AstraZeneca等頂尖科研機(jī)構(gòu)和制藥公司從事基礎(chǔ)研究和新藥研發(fā)團(tuán)隊(duì)領(lǐng)導(dǎo)者的工作經(jīng)歷，具有從靶點(diǎn)發(fā)現(xiàn)到臨床開發(fā)和商業(yè)運(yùn)作的整個(gè)研發(fā)價(jià)值鏈的研發(fā)背景。他博士畢業(yè)于中國人民解放軍空軍軍醫(yī)大學(xué)，在美國NIH完成博士后，其后還獲得美國Hood College工商管理碩士學(xué)位。他迄今在著名期刊上發(fā)表國際學(xué)術(shù)論文,專著章節(jié)和專利共30余篇，包括發(fā)表在Annals of the Rheumatic Diseases, Nature Communication, Nature Immunology, Nature Medicine, PNAS 等頂尖雜志上的論文。并曾獲得了衛(wèi)生部的科技進(jìn)步二等獎(jiǎng)，AstraZeneca的員工白金獎(jiǎng)和銀獎(jiǎng)，NIH的卓越研究員獎(jiǎng)，齊魯制藥集團(tuán)的卓越領(lǐng)導(dǎo)獎(jiǎng)等。Dr. Bo Chen is a specially-appointed expert for overseas high-level talents . He is currently the Chief Scientific Officer at China Resources Pharmaceutical Group Limited. He has more than 20 years of international career in the biotechnology and pharmaceutical industries, including basic research and innovative drug R&D team leadership in top scientific research institutions and pharmaceutical companies such as the National Institutes of Health, AstraZeneca, etc. He has R&D background in the entire R&D value chain from target discovery to clinical development and commercial operation. He received his PhD. degree from the Air Force Medical University (China), completed the postdoctoral fellowship at the National Institutes of Health in the United States, and later obtained an MBA degree from Hood College (U.S.A). He has published dozens of academic papers, book chapters and patents in peer-reviewed journals, including papers published in top journals such as Annals of the Rheumatic Diseases, Nature Communication, Nature Immunology, Nature Medicine, PNAS, etc. And has won the second prize of the Ministry of Health's Science and Technology Progress Award, the AstraZeneca Staff Platinum Award and Silver Award, the NIH Outstanding Researcher Award, Qilu Pharmaceutical Group's Outstanding Leadership Award, etc.